ArticlePharmaceutics2023
Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose.
Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 23 citations in OpenAlex.
- Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration.CPT: pharmacometrics & systems pharmacology · 2026Article
- Early anatomical rescue after switching to aflibercept 8 mg in faricimab-refractory neovascular AMD.International ophthalmology · 2026Article
- Aflibercept 8 mg in neovascular age-related macular degeneration and diabetic macular oedema: Translating clinical trials into clinical practice.Eye (London, England) · 2026Review
- Comparative outcomes of aflibercept 8 mg and faricimab in neovascular AMD refractory to aflibercept 2 mg.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- AI-assisted analysis of early fluid dynamics following aflibercept 8 mg in treatment-naïve neovascular AMD.Eye (London, England) · 2026Article
- Switching to High-Dose Aflibercept (8 mg) with Pro Re Nata Reduces Treatment Burden in Diabetic Macular Edema: A Real-World Pilot Study.Journal of clinical medicine · 2026Article
- One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.Ophthalmology and therapy · 2026Article
- Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification.Ophthalmology and therapy · 2026Article
- First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report.BMJ open ophthalmology · 2026Article
- Reassessing high-dose ranibizumab in the era of durable anti-VEGF therapy.Frontiers in ophthalmology · 2026Article
- Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Visual Gains with Faricimab vs Aflibercept 8 mg in Naïve Retinovascular Disease: Global Real-World Cases and Literature Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Reducing the Carbon Footprint of Neovascular Age-Related Macular Degeneration Therapy: Environmental Impact of Transitioning to Aflibercept 8 mg.Journal of ophthalmology · 2026Article
- Evaluation of the Duration of Good Visual Acuity During Anti-VEGF Therapy for Age-Related Macular Degeneration in Routine Clinical Practice.International journal of molecular sciences · 2025Article
- Early Outcome Analysis of Intravitreal Aflibercept 8 mg Treatment in Naïve Patients with Neovascular Age-Related Macular Degeneration Using Artificial Intelligence.Ophthalmology and therapy · 2025Article
- Extended duration of VEGF inhibition with aflibercept 8 mg: the role of reduced ocular clearance.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Novel Pharmacokinetic Bridging Strategy for Locally Acting Intravitreal Drug Products.The AAPS journal · 2025Article
- Early intraocular pressure dynamics following aflibercept 8 mg versus aflibercept 2 mg: a propensity score-matched analysis.Eye (London, England) · 2025Observational
- From pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD.Eye (London, England) · 2025Article
- Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report.BMC ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effects of various dosages and treatment regimens on intravitreal aflibercept concentrations and the proportion of free vascular endothelial growth factor (VEGF) to total VEGF were evaluated using a drug and disease assessment model. The 8 mg dosage received specific attention.
methodsA time-dependent mathematical model was developed and implemented using Wolfram Mathematica software v12.0. This model was used to obtain drug concentrations after multiple doses of different aflibercept dosages (0.5 mg, 2 mg, and 8 mg) and to estimate the time-dependent intravitreal free VEGF percentage levels. A series of fixed treatment regimens were modeled and evaluated as potential clinical applications.
resultsThe simulation results indicate that 8 mg aflibercept administered at a range of treatment intervals (between 12 and 15 weeks) would allow for the proportion of free VEGF to remain below threshold levels. Our analysis indicates that these protocols maintain the ratio of free VEGF below 0.001%.
conclusionsFixed q12-q15 (every 12-15 weeks) 8 mg aflibercept regimens can produce adequate intravitreal VEGF inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.